{
  "id": 4780075,
  "title": "How Is AbbVie’s Stock Performance Compared to Other Healthcare Stocks",
  "url": "https://urgent.news/2026/08/30/how-is-abbvies-stock-performance-compared-to-other-healthcare-stocks",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-30T19:21:04.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/markets/stocks/articles/abbvie-stock-performance-compared-other-192104509.html"
  },
  "original_language": "en",
  "account": "AbbVie Inc. (ABBV), a global biopharmaceutical company, trades at a market cap of $386.3 billion, categorizing it among mega-cap stocks. The company's key therapeutic areas encompass immunology, neuroscience, oncology, and aesthetics. Since April, ABBV has been trading beneath its 200-day moving average while maintaining an above-50-day average. In July, the company announced a strong Q2 2026, with revenue growing 10.2% year-over-year and adjusted EPS increasing 22.9%. However, investors are concerned about the near-term impact of ABBV's $10.9 billion Apogee Therapeutics acquisition, which is anticipated to dilute 2026 adjusted EPS by $0.14, partially offset by $0.10 of stronger-than-expected performance. Wall Street's sentiment on ABBV is moderately optimistic, with an overall consensus of \"Strong Buy\" from 31 analysts and a mean price target of $276.37, indicating an 8.2% potential upside from the current price.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}